Summit Therapeutics' HARMONi trial data for ivonescimab showed a clinical benefit but narrowly missed statistical ...

AstraZeneca AZN reported disappointing results from two late-stage studies that evaluated its investigational light chain ...

29 April 2025 EWHC ruling discusses application of EPO case law regarding lack of plausibility and lack of technical contribution | Court had earlier overturned a first-instance decision allowing an ...

"AstraZeneca’s AL amyloidosis drug fails to impress in Phase III" was originally created and published by Clinical Trials Arena, a GlobalData owned brand.

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival ...

Britain launched a life sciences sector plan on Wednesday to a mixed response from the pharmaceutical industry, which ...

An experimental AstraZeneca (NASDAQ:AZN) drug, anselamimab, failed to extend survival or cut heart-related hospitalizations in patients with a rare plasma cell disorder, disappointing hopes it could ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare ...

Anselamimab is a light chain depleter antibody which aims to treat light chain amyloidosis, a rare systemic and progressive disorder caused by defective plasma cells in bone marrow. The disease can ...

AstraZeneca said its amyloidosis treatment anselamimab failed to reach its primary goal in a final-stage trial.